Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

Component: Nanoparticle Core; Description: PEG-PLGA (methoxy PEG5k-PLGA15k) + cationic lipid DOTAP (1,2-dioleoyl-3-trimethylammoniumpropane)

Component: Particle Properties; Description: • Hydrodynamic diameter: 107.2 nm<br>• PDI: ~0.2<br>• Zeta potential: +15.3 mV<br>• Spherical vesicle structure with PEG shell<br>• Stable in 10% FBS for ≥5 days

Component: Plasmid Payload (pTyr-C9AP); Description: Tyrosinase promoter-driven co-expression plasmid encoding CXCL9 and αPD-L1 (anti-PD-L1 scFv) with P2A self-cleaving peptide; includes EGFP reporter for promoter activity

Component: Plasmid Payload (pSur-C9AP); Description: Survivin promoter-driven co-expression plasmid (universal tumor-specific promoter)

Component: Control Plasmids; Description: pTyr-CXCL9 (CXCL9 only), pTyr-αPD-L1 (αPD-L1 only), pUC57 (empty vector)

Component: αPD-L1 Design; Description: Anti-PD-L1 scFv with 6×His tag for detection

Component: Gene Delivery; Description: Intravenous injection; 1 mg plasmid/kg body weight; every other day for 5 injections

Component: Targeting Mechanism; Description: Promoter-driven tumor-specific expression (not particle targeting); NPs deliver to both tumor and normal tissues but promoters restrict expression to tumor cells

Component: Mouse Models; Description: B16-F10, Clone M-3, YUMM1.7 (melanoma); CT26 (colorectal); Panc02 (pancreatic); 4T1 (breast)

Component: Mouse Strains; Description: C57BL/6 (B16-F10, Panc02, YUMM1.7); BALB/c (CT26, 4T1)

Parameter: In Vitro Specificity; Details: 8 cell lines (B16-F10, CT26, Panc02, 4T1, C2C12, NIH/3T3, DC2.4, RAW264.7) transfected with NP_Tyr-C9AP; EGFP expression, CXCL9 and αPD-L1 mRNA/protein measured

Parameter: In Vivo Specificity (Tyr); Details: Bilateral tumor model: B16-F10 melanoma + Panc02 pancreatic tumor; i.v. NP_Tyr-C9AP; EGFP+ cells and CXCL9/αPD-L1 concentrations in tumors and organs

Parameter: In Vivo Specificity (Sur); Details: Four tumor models (B16-F10, CT26, Panc02, 4T1) + normal tissues; NP_Sur-C9AP; CXCL9/αPD-L1 concentrations measured

Parameter: T-Cell Recruitment Assay; Details: Transwell migration: supernatants from transfected B16-F10 cells in lower chamber; DiI-labeled CD8⁺ T cells in upper chamber; cell counting with Precision Count Beads

Parameter: PD-L1 Binding Assay; Details: IFN-γ-stimulated B16-F10 cells incubated with supernatants; αPD-L1 binding detected by anti-6×His tag antibody (flow cytometry)

Parameter: T-Cell Cytotoxicity Assay; Details: IFN-γ-stimulated B16-F10-OVA-EGFP cells + OVA-specific CD8⁺ T cells in culture supernatants; PI staining and CCK-8 for viability

Parameter: Transwell Migration + Cytotoxicity; Details: Combined assay: B16-F10-OVA-EGFP in lower chamber, OVA-specific CD8⁺ T cells in upper chamber; recruitment and killing measured

Parameter: Therapeutic Studies; Details: Tumor-bearing mice (n=6-10/group); 5 i.v. injections (every other day); tumor volume, weight, survival monitored

Parameter: Immune Profiling; Details: Flow cytometry: CD3⁺, CD4⁺, CD8⁺, CD69⁺, granzyme B⁺, perforin⁺, IFN-γ⁺ T cells; NK cells; MDSCs; Tregs; M1/M2 macrophage ratio

Parameter: Comparison to Anti-PD-L1; Details: Anti-PD-L1 antibody (2.5 mg/kg, i.v.) vs. NP_Tyr-αPD-L1 vs. NP_Tyr-C9AP vs. NP_Tyr-CXCL9 + anti-PD-L1

Parameter: Safety Assessment; Details: Body weight; H&E of major organs; ALT, AST, ALP (liver function)

Parameter: Sample Sizes; Details: n=4 (expression studies); n=6-10 (therapy studies); n=4 (toxicity)

Parameter: Statistical Tests; Details: Two-sided t-test; one-way ANOVA with Tukey's; two-way ANOVA with Greenhouse-Geisser; log-rank (Mantel-Cox)

Analysis Category: Nanoparticle Characterization; Methods: DLS (size, PDI, zeta potential); TEM (morphology); stability in 10% FBS

Analysis Category: Gene Expression; Methods: qRT-PCR (CXCL9, αPD-L1 mRNA); ELISA (CXCL9, αPD-L1 protein); Western blot (αPD-L1)

Analysis Category: Promoter Specificity; Methods: EGFP reporter fluorescence (microscopy, flow cytometry)

Analysis Category: T-Cell Recruitment; Methods: Transwell migration assay; DiI or Hoechst 33342 labeling; Precision Count Beads for absolute cell counting; CLSM imaging

Analysis Category: PD-L1 Binding; Methods: Flow cytometry: Alexa Fluor 647 anti-6×His tag antibody

Analysis Category: T-Cell Cytotoxicity; Methods: PI staining (flow cytometry); CCK-8 viability assay

Analysis Category: Flow Cytometry (Immune Profiling); Methods: Antibodies: CD45, CD3, CD4, CD8, CD69, NK-1.1/NKp46, CD11b, Gr-1, F4/80, CD80, CD206, Foxp3, CD25, granzyme B, perforin, IFN-γ; BD FACSCelesta; FlowJo v10.0.7

Analysis Category: Histology; Methods: H&E staining; multiple immunofluorescence (CD3, CD8, CD69); LSM880 confocal microscopy

Analysis Category: Liver Toxicity; Methods: ALT, AST, ALP ELISA kits (Rayto)

Analysis Category: Statistical Analysis; Methods: GraphPad Prism v8.0

Parameter: Hydrodynamic diameter; Value: 107.2 nm

Parameter: PDI; Value: ~0.2

Parameter: Zeta potential; Value: +15.3 mV

Parameter: Stability in 10% FBS; Value: ≥5 days (size/PDI stable)

Cell Type: B16-F10 (melanoma); EGFP+ Cells (%): 41.2%; CXCL9 (ng/mL): 0.47; αPD-L1 (ng/mL): 2.19

Cell Type: CT26 (colorectal); EGFP+ Cells (%): 3.2%; CXCL9 (ng/mL): Minimal; αPD-L1 (ng/mL): Minimal

Cell Type: Panc02 (pancreatic); EGFP+ Cells (%): <1%; CXCL9 (ng/mL): Minimal; αPD-L1 (ng/mL): Minimal

Cell Type: 4T1 (breast); EGFP+ Cells (%): <1%; CXCL9 (ng/mL): Minimal; αPD-L1 (ng/mL): Minimal

Cell Type: NIH/3T3 (fibroblast); EGFP+ Cells (%): 9.0%; CXCL9 (ng/mL): Minimal; αPD-L1 (ng/mL): Minimal

Cell Type: C2C12, DC2.4, RAW264.7; EGFP+ Cells (%): <1%; CXCL9 (ng/mL): Minimal; αPD-L1 (ng/mL): Minimal

Cell Type: Tyr promoter specificity; EGFP+ Cells (%): Melanoma-specific; CXCL9 (ng/mL): -; αPD-L1 (ng/mL): -

Tissue: B16-F10 melanoma; EGFP+ Cells (%): 9.11%; CXCL9 (ng/g): 12.12; αPD-L1 (ng/g): 43.12

Tissue: Panc02 pancreatic tumor; EGFP+ Cells (%): Few cells; CXCL9 (ng/g): Not increased; αPD-L1 (ng/g): Not increased

Tissue: Heart, liver, spleen, lung, kidney; EGFP+ Cells (%): Few cells; CXCL9 (ng/g): Not increased; αPD-L1 (ng/g): Not increased

Group: PBS; CD8⁺ T Cells Recruited (×10⁵): <0.1; CXCL9 (ng/mL): 0.02

Group: NP_Control; CD8⁺ T Cells Recruited (×10⁵): <0.1; CXCL9 (ng/mL): 0.02

Group: NP_Tyr-CXCL9; CD8⁺ T Cells Recruited (×10⁵): 1.26; CXCL9 (ng/mL): 0.44

Group: NP_Tyr-C9AP; CD8⁺ T Cells Recruited (×10⁵): 1.14; CXCL9 (ng/mL): 0.42

Group: PBS; Dead Cells (%): 1.9%

Group: NP_Control; Dead Cells (%): 1.3%

Group: NP_Tyr-CXCL9 (recruitment only); Dead Cells (%): 12.7%

Group: NP_Tyr-αPD-L1 (activation only); Dead Cells (%): 7.6%

Group: NP_Tyr-C9AP (both); Dead Cells (%): 45.8%

Group: PBS; Tumor Growth Inhibition Rate: -; Final Tumor Weight (% of PBS): 100%; Median Survival (days): ~27

Group: NP_Control; Tumor Growth Inhibition Rate: -; Final Tumor Weight (% of PBS): -; Median Survival (days): ~27

Group: NP_Tyr-CXCL9; Tumor Growth Inhibition Rate: 59.0%; Final Tumor Weight (% of PBS): 36.9%; Median Survival (days): 31

Group: NP_Tyr-αPD-L1; Tumor Growth Inhibition Rate: 69.5%; Final Tumor Weight (% of PBS): 29.5%; Median Survival (days): 30

Group: NP_Tyr-C9AP; Tumor Growth Inhibition Rate: 84.3%; Final Tumor Weight (% of PBS): 16.7%; Median Survival (days): 34

Parameter: CD3⁺ T cells (% of CD45⁺); PBS: ~5%; NP_Tyr-CXCL9: 10.4%; NP_Tyr-αPD-L1: 8.9%; NP_Tyr-C9AP: 21.4%

Parameter: CD3⁺ T cells (×10⁶/g tumor); PBS: ~0.4; NP_Tyr-CXCL9: ~0.8; NP_Tyr-αPD-L1: ~0.7; NP_Tyr-C9AP: 1.87

Parameter: CD8⁺ T cells (×10⁶/g tumor); PBS: ~0.2; NP_Tyr-CXCL9: ~0.4; NP_Tyr-αPD-L1: ~0.3; NP_Tyr-C9AP: 0.94

Parameter: CD69⁺ CD8⁺ T cells (×10⁵/g); PBS: ~0.5; NP_Tyr-CXCL9: ~0.5; NP_Tyr-αPD-L1: ~1.1; NP_Tyr-C9AP: 2.33

Parameter: Granzyme B⁺ CD8⁺ T cells (%); PBS: ~15%; NP_Tyr-CXCL9: ~25%; NP_Tyr-αPD-L1: ~35%; NP_Tyr-C9AP: 68.4%

Parameter: Perforin⁺ CD8⁺ T cells (%); PBS: ~10%; NP_Tyr-CXCL9: ~20%; NP_Tyr-αPD-L1: ~25%; NP_Tyr-C9AP: 53.2%

Parameter: IFN-γ⁺ CD8⁺ T cells (%); PBS: ~5%; NP_Tyr-CXCL9: ~10%; NP_Tyr-αPD-L1: ~15%; NP_Tyr-C9AP: 31.1%

Parameter: CD8⁺/Treg ratio; PBS: ~3; NP_Tyr-CXCL9: ~5; NP_Tyr-αPD-L1: ~6; NP_Tyr-C9AP: 13.37

Parameter: MDSCs (% of CD45⁺); PBS: High; NP_Tyr-CXCL9: Reduced; NP_Tyr-αPD-L1: Reduced; NP_Tyr-C9AP: Reduced

Parameter: M1/M2 macrophage ratio; PBS: Low; NP_Tyr-CXCL9: Increased; NP_Tyr-αPD-L1: Increased; NP_Tyr-C9AP: Increased

Group: Anti-PD-L1 antibody; Tumor Growth Inhibition Rate: 58.0%; Body Weight Change: Significant decrease

Group: NP_Tyr-αPD-L1; Tumor Growth Inhibition Rate: 64.2%; Body Weight Change: No significant change

Group: NP_Tyr-CXCL9 + anti-PD-L1; Tumor Growth Inhibition Rate: ~72%; Body Weight Change: Significant decrease

Group: NP_Tyr-C9AP; Tumor Growth Inhibition Rate: 78.2%; Body Weight Change: No significant change

Model: Clone M-3 melanoma; Tumor Growth Inhibition Rate: 69.5%

Model: YUMM1.7 melanoma; Tumor Growth Inhibition Rate: 56.0%

Tumor Model: B16-F10 melanoma; Tumor Growth Inhibition Rate: 84.4%; CD3⁺ T Cell Increase (vs. control): 16.8% of CD45⁺

Tumor Model: CT26 colorectal; Tumor Growth Inhibition Rate: 81.0%; CD3⁺ T Cell Increase (vs. control): 1.65×

Tumor Model: Panc02 pancreatic; Tumor Growth Inhibition Rate: 56.3%; CD3⁺ T Cell Increase (vs. control): 1.50×

Tumor Model: 4T1 breast; Tumor Growth Inhibition Rate: 66.5%; CD3⁺ T Cell Increase (vs. control): 3.67×

Parameter: Body weight loss; Result: None observed

Parameter: Major organ damage (H&E); Result: None detected

Parameter: Liver toxicity (ALT, AST, ALP); Result: No significant increase

1. Plasmid safety concerns: The authors acknowledge that "the safety risks of plasmids, including immunogenicity and potential gene insertion, need to be investigated before clinical use."

2. No tumor antigen presentation enhancement: The authors note that "the lack of tumor antigen presentation is not a major hurdle of αPD-L1 therapy," but also state that "some strategies targeting tumor antigen presentation can be combined to further enhance the efficacy of our strategy."

3. Nanoparticle liver accumulation: The authors acknowledge that "nanoparticles are unable to selectively deliver drugs into one specific type of organ or cell, and preferentially accumulate in liver," though promoter specificity mitigates this for gene expression.

4. αPD-L1 scFv lacks ADCC/ADCP: The authors note that "αPD-L1 scFv lacks antibody-dependent cellular cytotoxicity or phagocytosis (ADCC/ADCP) functions which may reduce its antitumor efficacy in comparison to αPD-L1 antibody," but counter that atezolizumab (which also lacks ADCC/ADCP) has shown good clinical efficacy.

5. In vivo imaging of expression: The study did not include real-time imaging of CXCL9/αPD-L1 expression dynamics or T-cell trafficking in vivo.

6. No depletion studies: The study did not include T-cell depletion experiments to formally prove that therapeutic efficacy is CD8⁺ T-cell-dependent (though strongly suggested by immune profiling).

7. Survivin promoter specificity: While survivin is overexpressed in most cancers, some normal tissues (e.g., proliferating cells) may have low-level expression, potentially leading to off-target expression in certain normal tissues.

8. Therapeutic models are subcutaneous: All tumor models were subcutaneous; efficacy in orthotopic or metastatic models was not demonstrated.

9. Species specificity: Mouse-specific promoters and αPD-L1 scFv were used; translation to human would require human promoters (e.g., hTERT) and humanized scFv.

10. Dosing optimization not explored: The study used a fixed dosing regimen (1 mg/kg, 5 injections); dose-response and schedule optimization were not performed.

11. No antigen-specific T-cell tracking: While T-cell infiltration and activation were characterized, the study did not track antigen-specific T-cell responses (e.g., tetramer staining).

12. Long-term safety: The study assessed acute toxicity but did not evaluate long-term safety, potential autoimmunity, or the durability of therapeutic responses beyond the treatment period.

Report prepared based on the published Nature Communications article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.